Early Phase 1 Multiple Myeloma Clinical Trials
26 recruitingEarly Phase 1
What is a Early Phase 1 trial?
Early Phase 1 trials are the earliest stage of testing in humans. These small studies focus on how a drug is processed in the body and how it affects the body, often enrolling just a handful of participants to establish initial safety data.
Showing 1–20 of 26 trials
Recruiting
Early Phase 1
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Multiple MyelomaRenal Failure
Augusta University30 enrolled1 locationNCT06142396
Recruiting
Early Phase 1
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Non-Hodgkin LymphomaMultiple MyelomaErdheim-Chester Disease+2 more
Memorial Sloan Kettering Cancer Center30 enrolled1 locationNCT05093335
Recruiting
Early Phase 1
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
Multiple MyleomaRefractory and Relapsed Multiple Myeloma
Wondercel Biotech (ShenZhen)30 enrolled1 locationNCT06663046
Recruiting
Early Phase 1
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Shenzhen Genocury Biotech Co., Ltd.9 enrolled1 locationNCT07336823
Recruiting
Early Phase 1
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
Multiple Myeloma
Peking University First Hospital30 enrolled1 locationNCT06385652
Recruiting
Early Phase 1
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University36 enrolled5 locationsNCT07294625
Recruiting
Early Phase 1
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China9 enrolled1 locationNCT07249073
Recruiting
Early Phase 1
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
Relapsed/Refractory Multiple MyelomaRelapsed/Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University24 enrolled1 locationNCT06730256
Recruiting
Early Phase 1
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Chronic Myeloid LeukemiaHodgkin LymphomaNon-Hodgkin Lymphoma+9 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins8 enrolled1 locationNCT06398457
Recruiting
Early Phase 1
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Non-Hodgkin Lymphoma (NHL)Multiple Myeloma (MM)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology40 enrolled1 locationNCT07101705
Recruiting
Early Phase 1
64Cu-LLP2A for Imaging Hematologic Malignancies
Chronic Lymphocytic LeukemiaMultiple MyelomaFollicular Lymphoma+4 more
Washington University School of Medicine42 enrolled1 locationNCT06636175
Recruiting
Early Phase 1
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
Multiple Myeloma (MM)Plasma Cell Leukemia (PCL)AL Amyloidosis (AL)
Anhui Provincial Hospital36 enrolled1 locationNCT07085559
Recruiting
Early Phase 1
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
Multiple MyelomaB-cell Lymphoma
YANRU WANG21 enrolled1 locationNCT06976437
Recruiting
Early Phase 1
A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
Multiple Myeloma and Malignant Plasma Cell Neoplasms
Peking University First Hospital50 enrolled2 locationsNCT06717113
Recruiting
Early Phase 1
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
Multiple MyelomaRelapsed/Refractory
The First Affiliated Hospital of Nanchang University12 enrolled1 locationNCT06999031
Recruiting
Early Phase 1
VitD3 Supplementation in Patients With Multiple Myeloma
Multiple Myeloma
Amany Keruakous, MD, MS.100 enrolled1 locationNCT05846880
Recruiting
Early Phase 1
A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology24 enrolled1 locationNCT06691685
Recruiting
Early Phase 1
A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Chunrui Li24 enrolled1 locationNCT06791681
Recruiting
Early Phase 1
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Multiple Myeloma
Oncotherapeutics30 enrolled1 locationNCT06209606
Recruiting
Early Phase 1
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Multiple MyelomaRelapsedRefractory
Shanghai Cell Therapy Group Co.,Ltd12 enrolled1 locationNCT06732232